Abstract
BackgroundPatients with relapsed/refractory osteosarcoma (OS) have dismal outcomes, and there are no systemic therapies that provide a survival benefit. Chimeric antigen receptor (CAR) T-cell immunotherapy involves the adoptive transfer of...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have